Trial Profile
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of a BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg Once Daily (qd) for 3 Days Assessing Pharmacodynamics as Endotoxin-induced Inflammatory Response of a Single Intravenous Bolus Administration of 2 ng/kg Body Weight Lipopolysaccharide (LPS). A Randomised, Double-blind Within Dose Groups, Placebo-controlled, Multiple Rising Dose Phase I Trial With Open-label Active Comparator in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2014
Price :
$35
*
At a glance
- Drugs BI 653048 (Primary) ; Prednisolone
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 27 Aug 2014 New trial record